Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $2.53
Previous CloseN/A
Volume775.41K
Average Volume (3M)915.91K
Market Cap
$40.61M
Enterprise Value$11.01M
Total Cash (Recent Filing)$18.21M
Total Debt (Recent Filing)$6.04M
Price to Earnings (P/E)―
Beta3.51
Next Earnings
Nov 05, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding58,721,590
10 Day Avg. Volume708,271
30 Day Avg. Volume915,914
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit1.07
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$10.00Price Target Upside1349.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe initiation of the first phase 3 trial for a CAB ADC would validate the broader technology.
Drug DevelopmentBioatla received feedback and alignment from the FDA on a phase 3 trial design and the potential for accelerated approval for Ozuriftamab Vedotin.
Market OpportunityThere is a large market opportunity for Ozuriftamab, and the company is actively seeking a strategic partner to advance the program.
Bears Say
Analyst RatingA Neutral rating is maintained on BCAB due to uncertainties regarding BioAtla's pipeline development and a near-term financial overhang.
Financial PerformanceBioAtla reported no revenue and a net loss of $0.32 per share, compared to the consensus estimate of a net loss of $0.29 per share.
Pipeline DevelopmentThere are uncertainties regarding BioAtla’s pipeline development, a near-term financial overhang, as well as lack of meaningful catalysts.
BioAtla News
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $0.24 and its highest was $2.52 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $40.61M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Nov 05, 2025 which is in 34 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Aug 07, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.04.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -0.3.
How many shares outstanding does BioAtla have?
BioAtla has 58,721,590 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went down -7.895%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
BioAtla Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (1349.28% Upside)
$10.00 (1349.28% Upside)
Blogger Sentiment
Bullish
BCAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 76.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.60%
12-Months-Change
Fundamentals
Return on Equity
-813.88%
Trailing 12-Months
Asset Growth
-60.48%
Trailing 12-Months
Company Description
BioAtla
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB Company Deck
BCAB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented notable scientific and regulatory advancements, particularly with BA3182 and Oz-V, and strategic partnerships aimed at non-dilutive funding. However, financial constraints, including decreased cash reserves and ongoing net losses, underline significant operational challenges.View all BCAB earnings summariesBCAB Stock 12 Month Forecast
Average Price Target
$10.00
▲(1349.28% Upside)
Technical Analysis
Lisata Therapeutics
―
ProMIS Neurosciences
―
MindWalk Holdings
―
Elevation Oncology
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
9.35% Insiders
4.07% Mutual Funds
12.03% Other Institutional Investors
70.47% Public Companies and
Individual Investors